Hem

Press release from Companies

Publicerat: 2022-07-08 14:18:55

Eevia Health Plc: Eevia Health Plc being followed by Analyst Group

Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").

 

The financial analyst Rosan Tekin and the equity research firm Analyst Group started tracking Eevia and issued a first equity analysis report last week. The report can be found here:

 

https://www.analystgroup.se/wp-content/uploads/2022/06/Analyst-Group-Eevia-Health.pdf

 

Analyst Rosan Tekin summarized the investment case:

 

"Eevia Health offers organic plant extracts for food nutraceuticals, drinks, and cosmetics under different brands. The Company is at a stage where it aims to increase production capacity, focus on higher-margin extracts, and develop new proprietary ingredients targeting eye disorders, which could be strong value drivers ahead. Having a broad product portfolio and high demand from customers, Eevia Health is entering a fast-growth phase, where an EBIT of EUR 4.8m is estimated in 2026. Based on an applied EV/EBIT multiple of 5x on estimated EBIT, and a discount rate of 14%, this yields an equity value per share of SEK 8.8 in a Base scenario. In conclusion, we see several drivers as well as market trends in Eevia’s favor, and where steps in the right direction should reduce the current valuation discount."

 

 

The Analyst Group comment related to Eevia Health Plc is made on their behalf. Readers may assume that Analyst Group has received compensation for making the comment, but Eevia has not had any opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.

 

 

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          

Email: stein.ulve@eeviahealth.com                      

Telephone: +358 400 22 5967                               

 

  

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia’s other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

 

INFORMATION ABOUT ANALYST GROUP AB

 

About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.

 

Read more about Analyst Group here: Startsida - Analyst Group

 

Läs mer hos Cision
Läs mer om Eevia Health Plc

Prenumeration